secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015552
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022
--------------------------------------------------------------------------------

- Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).
- R&D expenses $38.5M, up from $17.7M YoY due to VAX-24/VAX-XP/Phase 3 readiness activities.
- Net loss $48.5M for Q2 2022 compared to $23.7M in Q2 2021.
- Completed enrolment of Phase 2 portion of VAX-24 proof-of-concept study in adults 50-64 (≈800 subjects).
- FDA granted Fast Track designation for VAX-24 in adults; topline results expected Oct or Nov 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/0000950170-22-015552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017022015552/pcvx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer